cyrilzakka/clinical-trials huggingface dataset:
The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease

Here investigators will carry out this phase II clinical trial to explore a effective therapeutic regimen of MSC in the Crohn's perianal fistula.

Peri-anal fistula is common seen in Crohn's disease. Treatments including surgery, antibiotics, immunosuppressive drug and infliximab improve the quality of life of the patients suffering Crohn's perianal fistula, but the recurrent rate is still high. MSC showed promising effect in the therapy of CD, but the standard treatment strategy is unclear. Here investigators will carry out this phase II clinical trial to explore a effective therapeutic regimen of MSC in the Crohn's perianal fistula.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18-65 years old, male or female;
2. refractory CD fistula, there are 1-2 and 1-3 in the mouth fistula;
3. Diagnostic CD at least three months;
4. CDAI \<250;
5. were receiving drug treatment (5-ASA and hormones\> 4 weeks, immunosuppressants and biological agents\> 8 weeks);
6. signed informed consent.

Exclusion Criteria:

1. with intestinal obstruction, stenosis, or perianal abscess;
2. pregnant or lactating women;
3. infection needs antibiotics persons;
4. rectovaginal fistula;
5. complex anal fistula more than two inside the mouth;
6. stenosis or perforation CD;
7. perianal infection;
8. could not do rectal or anal stenosis local injection therapy;
9. with acute enteritis;
10. , liver and kidney dysfunction;
11. a month have used other drugs are in clinical trials;
12. no conditions or unwilling to carry out MRI inspected;
13. who are adjusting therapy;
14. HIV patients;
15. The combined active hepatitis or tuberculosis; Occurred in 16) 6 months opportunistic infections, or severe infections occur within three months;

17) In the past five years, those who suffer from cancer; 18) there is a history of lymphoproliferative disease.
Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques

The main objective of this study is to compare results for the detection of circulating melanoma cells (CMC) using CellSearch versus EPISPOT (EPithelial ImmunoSPOT) techniques between a group of patients with metastatic melanoma and a group of hospitalized control patients.

The secondary objectives of this study include:

A. To compare the following elements between the two patient groups:

* the number of CMCs per ml of blood as determined by EPISPOT
* the number of CMCs per ml of blood as determined by CellSearch
* the percentage of patients with at least 2 CMCs per ml of blood according to the two techniques
* the % of CMCs expressing KI67
* the % of CMCs expressions S100 (only the EPISPOT technique)

B. To compare the EPISPOT and CellSearch techniques is terms of the following:

* the number of CMCs detected per ml blood
* the number of CMCs expressing antigen KI67

C. To re-evaluate the 2-CMC per ml blood threshold

Eligibility Criteria:
Inclusion Criteria:

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* The patient is available, within the hours of his/her normally scheduled medical care, for blood sampling at 8 am and 4 pm on the same day.

Inclusion Criteria for patients:

* Stage 4 melanoma, without other associated neoplasms

Inclusion Criteria for controls:

* Patient without cancer, nor history of cancer

Exclusion Criteria:

* The patient is participating in another study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* The patient is pregnant, parturient, or breastfeeding
* The patient has a contra-indication for a treatment used in this study

Exclusion criteria for patients:

* Stage 1 to 3 melanoma, or other types of cancer

Exclusion criteria for controls:

* History of cancer
Translation and Validation of the Performance Oriented Mobility Assessment (Poma) Scale Into Urdu Version

The aim of this study is to translate the original English version POMA scale into Urdu and also determine cultural adaptation to establish its validity and reliability. This study also aims to correlate Performance oriented Mobility Assessment (POMA) scales with time up and go test in elderly population.

Among older persons, age-related impairments cause loss of postural control and balance that result in pain, independency and disability. One of the most common geriatric syndromes and most serious health issue threatening the independency of older persons is fall. The impact of these fall-related injuries on older person, families and societies and its fruitful intervention has made this issue important worldwide. Approximately 28-35% of people aged 65 years and 32-42% of aged 70 years' experience falls annually and 10% suffer serious injury such as, fracture, severe head trauma and joint dislocation. The incidence rate of fall is higher in hospitalized and residents of nursing home. It rises from middle age and peaks in person above 80 years. The risk factors associated with falls are, lower extremity muscle weakness, gait or balance deficits, use of an assistive device, cognitive impairment, visual deficit, arthritis and impaired activities of daily living . Different scales and tests are used for risk factors for falls, balance and mobility such as Berg Balance Scale, Time up and go test and dynamic gait index and Fullerton Advanced Balance Scale. One of these scales Performance-Oriented Mobility Assessment (POMA) scale. POMA scale has acceptable reliability and validity as compared to FRT and TUG in elderly. The advantages of this scale are; applicability, low cost, easy to administer, no equipment is needed other than a standard chair and stopwatch, evaluates functional activities and assesses both balance (POMA-B) and gait components (POMA-G)Originally POMA scale was used to assess risk of fall in institutionalized populations but later on used as an assessment tool for mobility and determine effects of interventions.

The POMA has found to be widely used in patients who have dynamic and reactive balance deficits. It comprises 16 items (9 balance and 7 gait related). Total time taken for administration is approximately 10 minutes and total score is 28; 16 is balance and 12 is gait score. Some Items are scored dichotomously (can/cannot perform) and others are scored 0, 1 or 2 points for quality of performance. The higher scores show low fall risk and better balance while lower score predicts poorer balance and greater risk of fall. The score 19-24/28 indicates moderate risk for falling while score \<19 indicates a "high" risk for falling.

Eligibility Criteria:
Inclusion Criteria:

* The sample will be assessed a cognition evaluation through the mini-mental test
* Any present or previous history of vertigo since last 6 months

Exclusion Criteria:

* Patients with any neurological disorder,
* previous orthopedic surgery within last 6 months,
* bedridden,
* wearing any prosthesis, and illiteracy.
CHM Teabag Decrease Stroke Risk Among Hong Kong Elderly

This stepped wedge cluster randomized controlled trial aims to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population.

This is a stepped wedge cluster randomized controlled trial design. This study aims to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population.

A total of 912 participants will be recruited from 9 clinics. 2\~3 clinics will represent a cluster unit. The stepped wedge design will consist of four groups each containing four randomly allocated cluster units, allocated to either 4, 8, 12, or 16 weeks of the intervention. The intervention is Chinese herbal teabag treatment, which will consist of five Chinese herbs (a total of 10g). The first group will receive 16 weeks of the intervention, the second group will receive 12 weeks, the third group will receive 8 weeks, and the forth group will receive 4 weeks.

The primary outcome measure is the stroke risk estimated with Automatic Retinal Image Analysis (ARIA). Secondary outcome measures include Framingham Stroke Risk Score (FSRS), cognitive impairment risk estimated with ARIA, Hong Kong version of the Montreal Cognitive Assessment (MoCA), Constitution in Chinese Medicine Questionnaire (CCMQ), World Health Organization Quality-of-Life Scale (WHOQOL-BREF), Health-promoting lifestyle profile II (HPLP-II), and adverse events.

Eligibility Criteria:
Inclusion Criteria:

* Age between 54-84y.
* With phlegm dampness constitution and blood stasis constitution on the TCM constitution test table.
* Stable vital signs without previous history of stroke.
* Sufficient sensorimotor and language competency for completing assessments.

Exclusion Criteria:

* Allergic history to Chinese herbal drugs or a known allergy to the ingredients of the teabag.
* Taking any anticoagulants, such as warfarin.
* With unconsciousness, aphasia, and cognitive dysfunction.
* With a past history of brain diseases (e.g., mental illness, consciousness disorder due to head trauma, previous brain surgery, or spastic disease).
* With severe heart, liver, or kidney disease or bleeding disorders.
* With other serious diseases.
* Cataracts or other eye diseases that affected retinal image taking.
* Distressed with a flashlight or have experience with photosensitive seizures.
* Pregnancy or lactation female.
* Any physical examination findings, or history of any illness, or concomitant medications that, in the opinion of the study investigator, might not be suitable to participate in the study.
Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy

A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy


Eligibility Criteria:
Inclusion Criteria:

-Histologically or cytologically confirmed unresectable locally advanced NSCLC with progressed or recurred after no more than four previous docetaxel-free chemotherapy regimens, or unresectable locally advanced or metastatic SCCHN or recurred after previous docetaxel-free chemotherapy regimens

Exclusion Criteria:

1. Women who are nursing or pregnant during the study period;
2. Patients with carcinoid tumors, small-cell carcinoma of the lung;
3. A history of another malignancy within the last five years (except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the uterine cervix);
4. Any other morbidity or situation with contraindications for chemotherapy (e.g. active infection, myocardial infarction in the preceding 6 months);
5. Neutrophil counts \< 1,500 cells/mm3;
6. A history of hypersensitivity to docetaxel or cisplatin;
7. Symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias;
8. Subjects have active hepatitis;
9. Subjects are known positive for Human Immunodeficiency Virus (HIV);
10. Any condition judged by investigator, participates the study will jeopardize patient's wellbeing
Comparing Two Different Rehabilitation Protochols on Patients With Rotator Cuff Repair

Rotator cuff (RC) repair is one of the most common treatment approch to relief the pain and improve the shoulder function on patients with rotator cuff rupture. Despite the improved surgical techniques and decreased failure rate, there are still complications after the surgey like shoulder persistant shoulder pain, stiffness even re-tear. Therefore, rehabilitation after the RC repair procedure is crucial for the success of the treatment. However, there is no concencus between the post-operative rehabilitation protochol. The aim of this study is to compare two different rehabilitation protochols on patients with RC repair.

Rotator cuff (RC) repair is one of the most common treatment approch to relief the pain and improve the shoulder function on patients with rotator cuff rupture. Despite the improved surgical techniques and decreased failure rate, there are still complications after the surgey like shoulder persistant shoulder pain, stiffness even re-tear. Therefore, rehabilitation after the RC repair procedure is crucial for the success of the treatment. However, there is no concencus between the post-operative rehabilitation protochol. The aim of this study is to compare two different rehabilitation protochols in terms of shoulder range of motion, self-reported shoulder function and pain on patients with RC repair.

Eligibility Criteria:
Inclusion Criteria:

* Having a Rotator Cuff repair surgery
* Having post-op rehabilitation program at our clinic until post-op 3 months
* No previous surgery in the shoulder joint

Exclusion Criteria:

* Additional pathology other then RC tear
* Refusing to participate to the study
Improvement of Knowledge About the Arthrogenic Muscle Inhibition in the Aftermath of Knee Trauma.

Arthrogenic Muscle Inhibition (AMI) is one of the classic complications occurring in the aftermath of knee trauma; AMI is grossly defined as a lack of extension due to quadriceps inhibition and hamstring contracture. However, its origins remains unknown with a strong suspicion for a central brain origin. It could be the missing link explaining this lack of extension following an anterior cruciate ligament (ACL) rupture. The primary hypothesis of this study is that a difference in activation of motor brain areas exists in patients with an ACL rupture, between those with AMI or without. The second hypothesis is that this difference could be seen on brain functional MRI.

AMI leads to quadriceps atrophy, persistent knee pain, dynamic instability, and a higher rate of osteoarthritis. A recent literature review suggests that the AMI phenomenon is multifactorial, but not widely known and poorly understood. Known mechanisms include impaired motor function at rest, impaired transmission of information from joint sensory receptors, impaired excitability of the spinal reflex and impaired cortical activity. Several studies have suggested a link between ACL rupture and central nervous system reorganization. Among the neurophysiological investigations explored are the evoked somesthesic potentials, electroencephalography, and transcranial magnetic stimulation (TMS). However, these mechanisms alone do not explain the phenomenon in its entirety, suggesting that there are other mechanisms. Furthermore, no study has used functional brain MRI to assess the existence of similar changes in AMI.

This study plans to compare two groups of patients with an ACL rupture: a group with AMI, and a group without AMI. Both groups will undergo a functional brain MRI in order to analyse any modification of the sensory-motor network connectivity that could occur.

Eligibility Criteria:
Inclusion Criteria:

* male patient, right-handed,
* with a severe right knee sprain in the event of ACL rupture,
* occurrence of trauma within 4 weeks prior to inclusion,
* with a score of ≥ 8/10 on the Edinburgh Manual Laterality Questionnaire, -affiliated or benefiting from public health services.

Exclusion Criteria:

* person presenting any of these conditions : professional player / athlete, -contraindication to the MRI examination (claustrophobic patient, patient with a metallic element),
* patient already operated on with ligament damage to the knee other than ACL,
* patient with iterative ACL rupture,
* patient who has undergone contralateral ligament reconstruction,
* patient with multi-ligamentary knee injury,
* patient refusing to be informed of any abnormality detected on brain MRI, -protected patient (adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision).
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

This project anchors osteoporotic fractures, conduct registration and follow-up studies, and conduct prospective treatment studies. By registering for follow-up studies on osteoporotic fractures, it is planned to obtain epidemiological data through registration and follow-up studies; A prospective treatment study for patients with osteoporotic fractures is planned to explore effective treatment strategies through randomized controlled trials; To study biomarkers for osteoporotic refractures, we plan to establish a biomarker warning model through multi omics research; To study imaging biomarkers for osteoporotic refractures, a new imaging technology is proposed to establish an imaging omics warning model.


Eligibility Criteria:
Inclusion Criteria:

1. New brittle hip fractures;
2. New brittle vertebral fractures;
3. New other site fractures and/or total hip or neck of femur or L1-L4 T-value \&lt; -1.0;
4. Men or postmenopausal women;
5. Age 45-90 years old;
6. Ability to move autonomously

Exclusion Criteria:

1. bone metabolic diseases except for osteoporosis eg. a. (Osteogenesis Imperfecta, Paget's disease, Osteomalacia), b. Cushing's syndrome, c.hyperprolactinemia;
2. Having primary hyperparathyroidism or hypothyroidism;
3. Had or have osteomyelitis of the jaw or necrosis of the jaw;
4. GFR\<30ml/min/1.73m2;
5. Active infection that requires systematic treatment;
6. Used intravenous bisphosphonate, fluoride, or strontium for osteoporosis within 2 years;
7. Used teriparatide and denosumab for osteoporosis within 6 months;
8. Used glucocorticoids (equivalent to \&gt;5 mg/day prednisone) for more than 10 days within 6 weeks;
9. The time gap between the first time and the last time oral bisphosphonate for osteoporosis less than 1 year( if used within one year, but the cumulative use is ≤ 1 month, the subject can be enrolled) ;
10. Patients with malignant tumors or bone metastases within 5 years, except tumors that are expected to be cured after treatment;
11. Have hypocalcemia and hypercalcemia;
12. Unexplained elevation of alkaline phosphatase;
13. A serious deficiency of vitamin D (25OHD \&lt;10ng/mL);
14. Patients who have previously received external radiation or radiation therapy with bone implants;
15. Uncontrolled comorbidities included heart failure above the New York cardiac Function Scale, glycosylated hemoglobin \&gt; 8.5%, and severe arrhythmias;
16. Planned pregnancy and lactation at present or during the study period;
17. Allergic to teriparatide and denosumab;
18. Participating in clinical trials of other drugs at present;
19. subjects do not suitable for this study
Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke

This pilot trial will be the first step toward direct comparison of delivery of endovascular reperfusion therapy to intravenous recombinant tissue plasminogen activator (rt-PA) in a time-to-treatment framework shown as most effective by the NINDS rt-PA Stroke Trial. A randomized trial is justified for the following reasons: 1) The high rate of death and disability associated with ischemic stroke despite treatment with intravenous rt-PA mandates critical analysis of alternate therapies with therapeutic potential, 2) endovascular treatment for acute ischemic stroke is expanding in North America without compelling evidence of safety and efficacy from well-designed clinical trials, 3) critical cost-effectiveness analysis cannot be done without acquiring pertinent outcomes data from controlled studies.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Definite or probable ischemic stroke
* CT angiographic (CTA) evidence of intracranial vascular occlusion (internal carotid, middle cerebral - M1 or M2 divisions, anterior cerebral, posterior cerebral, or basilar artery) within 3.5 hours of symptom onset
* Able to receive assigned treatment within 4.5 hours of symptom onset
* Written informed consent from patient or surrogate, if unable to provide consent

Exclusion Criteria:

* CT evidence of early infarction in \>1/3 of middle cerebral artery distribution
* Blood pressure \> 185/110 mmHg refractory to anti-hypertensive therapy
* History of intracranial hemorrhage
* History of ischemic stroke within past 3 months
* History of major surgical procedure within past 14 days
* Gastrointestinal or genitourinary bleeding within past 14 days
* Glucose \<50 or \>400mg/dL
* Platelet count \<100,000
* International normalized ratio (INR) ≥ 1.7
* Known history of bleeding diathesis
Prevention of Ovarian Cancer in Women Participating in Mammography

The primary purpose of this study is to evaluate the effect of systematic identification and genetic counseling referral on rates of bilateral salpingo-oophorectomy (surgery to remove both fallopian tubes and ovaries) in women having mammograms at Swedish Medical Center in Seattle, WA.


Eligibility Criteria:
Inclusion Criteria:

* Prior mammogram at Swedish Medical Center
* Willing and able to provide informed consent, primary physician information, and complete study questionnaires
* Must meet at least ONE of the following criteria:
* personal history of breast cancer diagnosed before age 50
* personal history of bilateral breast cancer at any age
* 1 or more first degree relatives with breast cancer diagnosed before age 50
* 3 or more first or second degree relatives with breast cancer at any age
* 2 second degree relatives with breast cancer diagnosed before age 50
* A male relative with breast cancer at any age
* Ashkenazi Jewish with any family history of breast or ovarian cancer
* 1 first or second degree relative with ovarian cancer AND 1 first or second degree relative with breast cancer at any age
* 2 first degree relatives with ovarian cancer or 2 second degree relatives with ovarian cancer or 1 first and 1 second degree relative with ovarian cancer.
* A first degree relative with both breast and ovarian cancer (2 primaries in the same person)
* Personal history of positive genetic test result for any of the following genes: BRCA1, BRCA2, HNPCC, or P53
* Family history of a positive genetic test result for any of the following genes: BRCA1, BRCA2 or HNPCC

Exclusion Criteria:

* Previous diagnosis of ovarian cancer
* Prior bilateral-salpingo oophorectomy
* Had a negative genetic test result for a known family genetic mutation
Regional Anesthesia for Percutaneous Transluminal Angioplasty

In this study, the effects of regional anesthesia method applied in patients who will undergo percutaneous transluminal angioplasty for lower extremity revascularization will be investigated comparatively.


Eligibility Criteria:
Inclusion Criteria:

* Age: \> 18 years
* Peripheral artery occlusive disease
* Eligibility for PTA

Exclusion Criteria:

* Patients' refusal
* Under the age of 18
* Language problems (not knowing turkish)
* Psychological or mental disorders.
* Disturbance of Conscious level.
* Uncooperative patients
* Those who are allergic to anesthetic drugs to be used
* Those with contraindications for the application of peripheral nerve block (coagulopathy, skin infection at the block site)
* need for endotracheal intubation or general anesthesia